tiprankstipranks
pc:cha4s

CHARM Therapeutics

London, GB
https://www.charmtx.com/
CHARM Therapeutics is a biotechnology company focused on developing next-generation precision oncology treatments, specifically targeting acute myeloid leukemia (AML). Utilizing its proprietary AI-driven drug discovery platform, DragonFold, CHARM is advancing a novel menin inhibitor designed to overcome resistance mutations that limit the efficacy of first-generation therapies. The company's innovative approach aims to provide more durable and effective treatment options for AML patients, with clinical development of its lead candidate expected to commence in early 2026. Based in Cambridge and London, CHARM is supported by a strong syndicate of international investors.

Leadership & Board

Current Number of Employees33
Current LinkedIn Followers12,945

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$80M
Total Amount Raised$80M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$80M
Latest Funding Amount$80M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Employee Trend

CHARM Therapeutics had 33 employees as of May 4, 2026. The number of employees increased by 0 (0.00%) week-over-week.
33Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

CHARM Therapeutics had 12,945 followers as of May 4, 2026. The number of followers increased by 25 (0.19%) week-over-week.
12,945Latest Followers Count
25(0.19%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Sep 02, 2025
Series B
$80.00M

Investors

Investor Name
Funding Round
Series B
Series B
Series B
Series B

Related News and Analysis